Your browser doesn't support javascript.
loading
Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy.
Li, Guan-Zhang; Zhang, Ke-Nan; Wang, Zheng; Hu, Hui-Min; Wang, Zhi-Liang; Huang, Ruo-Yu; Jiang, Hao-Yu; Zhai, You; Feng, Yue-Mei; Chang, Yuan-Hao; Li, Ren-Peng; Wu, Fan; Zeng, Fan; Jiang, Tao; Zhang, Wei.
Afiliación
  • Li GZ; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Zhang KN; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Wang Z; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, People's Republic of China.
  • Hu HM; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Wang ZL; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Huang RY; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Jiang HY; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, People's Republic of China.
  • Zhai Y; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Feng YM; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Chang YH; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Li RP; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, People's Republic of China.
  • Wu F; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Zeng F; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Jiang T; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, People's Republic of China.
  • Zhang W; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, People's Republic of China.
Onco Targets Ther ; 12: 10263-10273, 2019.
Article en En | MEDLINE | ID: mdl-31819511
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Onco Targets Ther Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Onco Targets Ther Año: 2019 Tipo del documento: Article